CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Stoic VC

Geoff Waring, Founding Partner

Preventing Destructive Conflict between Investors on Your Board

Geoff Waring

Geoff Waring

Board Conflict Advisor

Bow do founders prevent destructive conflict between investors on their start-up board? You hear stories of co-founders with unresolved conflict between them that damages their business. But investors can get into unresolved conflicts with each other too.


The standard legal solutions are a constitution and a shareholders’ agreement that formalises expectations. These do help. But they are not enough when interests diverge as large investments are at stake. A natural alignment of interests is more important than enforcing them. But how do founders achieve this between their investors?


Founders should prefer VC firms which have coinvested together previously without destructive results for the company.


Investors who successfully co-invest regularly are less likely to end up in conflict than VC firms that have never co-invested. Expected repeat interactions create incentive for cooperative, non-destructive resolutions. At Stoic VC for example we emphasise collaboration and have co-invested in 20 companies with Uniseed with no destructive conflict between us so far. This means founders we invest in don’t have to worry about investor conflict between us damaging their company at a later stage.


The standard legal solutions are a constitution and a shareholders’ agreement that formalises expectations


Founders should prefer investors that are similar to each other so their interests are aligned


Investors that are similar on key parameters such as fund size, type of limited partners and years left till the end of their fund life will less likely conflict as their incentives are similar.


Investors with different sized funds under management will more likely disagree about when to accept an acquisition offer. For example I have seen inter-investor conflict arise between angel investors and VC funds.


The angels have fewer funds, so invest less in each company and earlier so are more likely in the money if the company sells at a lower valuation. A large VC fund with a larger and later stage investment in the company will more likely reject the offer and hope for a larger exit later.


Funds with different limited partners may put more emphasis on their limited partner mandates and thus create conflict e.g. a government funded venture fund may prefer to keep the investee company’s headquarters in the home country whereas an overseas investor may prefer to move the headquarters to their larger home market.


VC investors that have significant differences in the time left in their fund will have different investment horizons. A typical venture capital fund life is 10 years. Those with fewer years left in their fund life (say 6 years in with 4 years to go) will push for a faster exit option by their portfolio companies than would a fund with more years to go, even though the later exit may have higher present value. Our fund made investments where individual angel investors with short horizons pressured the founders to pay dividends rather than invest more and grow faster. In 2021 Sequoia Capital in the US moved to an evergreen fund to avoid this conflict with founders. But this means they conflict more with other investors with a 10 year fund.


Founders can use “Pay to Play” terms in later funding rounds


Investors get into disagreements when some provide followon finance while others do not. To align these investors, founders should include terms in later funding rounds that punish investors that do not follow-on. A typical punishment is converting preference shares to ordinary shares for investors who do not follow on. The first time I saw these provisions in a round I was shocked at how draconian they were. But I appreciate those investors that do not follow on hurt the company, so the pay to play terms that transfer wealth of investors that do not follow on to shareholders that follow on better align interests.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.

Editorial Lens

Startup boards can become fragile when investor incentives diverge during financing, governance or exit decisions. Waring’s perspective gives life sciences founders and investors a practical lens on why alignment, co-investor history and funding terms must be managed before conflict harms company progress.

The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/preventing-destructive-conflict-between-investors-on-your-board-nwid-1529.html